Abstracts tagged "Systemic sclerosis"

Abstract Number: 0699 • ACR Convergence 2024
Cardiac Biomarkers for Predicting Cardiopulmonary Toxicity of Autologous Haematopoietic Stem Cell Transplantation for Systemic Sclerosis
Ross Penglase¹, Samadhi Gunawardhana¹, Graham Jones¹, Andrew Jabbour¹, Eugene Kotlyar¹, Laila Girgis², David Ma¹ and John Moore¹, ¹St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia, ²St Vincent's Hospital, Sydney, Darlinghurst, New South Wales, Australia
Background/Purpose: Autologous Haematopoietic Stem Cell Transplantation (AHSCT) is an effective treatment for severe systemic sclerosis (SSc), with demonstrated benefit for pulmonary and cutaneous outcomes and…
Abstract Number: 0955 • ACR Convergence 2024
Inhibition of Interleukin-2-Inducible T Cell Kinase with Soquelitinib Demonstrates Efficacy in Preventing Lung Damage in Murine Models of Systemic Sclerosis
Goncalo Boleto¹, Anne Cauvet², James Rose³, Lih-Yun Hsu³, Richard A. Miller³ and Yannick Allanore⁴, ¹Rheumatology Department, Unidade Local de Saúde Santa Maria, Centro Académico de Medicina de Lisboa, Lisboa, Portugal., Lisbon, Portugal, ²Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, France, ³Corvus Pharmaceuticals, 863 Mitten Road, Burlingame, Burlingame, CA, ⁴Université Paris Cité, Paris, France
Background/Purpose: T cells abnormal activation plays a pivotal role in the early inflammatory stages of systemic sclerosis (SSc). Compelling evidence supports that SSc has a…
Abstract Number: 1559 • ACR Convergence 2024
Vectorcardiography for Identification of Systemic Sclerosis Patients at Risk for Pulmonary Hypertension
S. Ahmed¹, Eva Hoekstra², Katie van der Wouden², Sum-Che Man², Kees Swenne², Madelon Vonk³, Anna-Maria Hoffmann-Vold⁴, Cosimo Bruni⁵, Udo Mulder⁶, Thomas Huizinga⁷, H.W. Vliegen² and Jeska de Vries-Bouwstra², ¹Leiden University Medical Centre, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Oslo University Hospital, Oslo, Norway, ⁵University of Zurich, Zurich, Switzerland, ⁶Universitair Medisch Centrum Groningen, Groningen, Netherlands, ⁷Department of Rheumatology, Leiden University, Leiden, Netherlands
Background/Purpose: Pulmonary hypertension (PH) in SSc causes significant disease burden and requires invasive diagnosis with right heart catheterization (RHC). Comprehensive work-up is needed to identify…
Abstract Number: 1582 • ACR Convergence 2024
Impact of Immunosuppressive Treatment on Development and Survival in Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)
Stefano Rodolfi¹, Cheryl Chun Man Ng², Ana Maria Ruiz Bejerano², Medha Kanitkar², Voon Ong³ and Christopher Denton⁴, ¹Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ²University College London, London, United Kingdom, ³University College London, London, England, United Kingdom, ⁴University College London, Northwood, United Kingdom
Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe and frequently life-threatening complication of systemic sclerosis (SSc). Treatment of SSc-PAH follows the same approach of idiopathic…
Abstract Number: 1822 • ACR Convergence 2024
Analysis of Differential Activation of Lysophosphatidic Acid Regulated Genes in Diffuse and Limited Cutaneous Systemic Sclerosis
Medha Kanitkar¹, Philip Yee², Stefano Rodolfi¹, Kristina Clark³, Voon Ong⁴ and Christopher Denton⁵, ¹University College London, London, United Kingdom, ²UCL, London, United Kingdom, ³University of Oxford, Oxford, United Kingdom, ⁴University College London, London, England, United Kingdom, ⁵University College London, Northwood, United Kingdom
Background/Purpose: Lysophosphatidic Acid (LPA) is a lipid mediator implicated in the pathogenesis of SSc and idiopathic pulmonary fibrosis. Phase 2 clinical trials targeting this biological…
Abstract Number: 2205 • ACR Convergence 2024
Presence of Nailfold Capillary Changes Correlates with More Severe Organ Involvement in Juvenile Systemic Scleroderma. Results of the Juvenile Scleroderma Inception Cohort
Ivan Foeldvari¹, Jens Klotsche², Kathryn Torok³, Ozgur Kasapcopur⁴, Amra Adrovic⁵, Brian Feldman⁶, Jordi Anton⁷, Sindhu R. Johnson⁸, Flavio Sztajnbok⁹, Maria Teresa Terreri¹⁰, Ana Sakamoto¹¹, Valda Stanevica¹², Dieneke Schonenberg-Meinema¹³, Ekaterina Alexeeva¹⁴, Maria Katsicas¹⁵, Raju Khubchandani¹⁶, Sujata Sawhney¹⁷, vanessa smith¹⁸, Eslam Al-Abadi¹⁹, Simone Appenzeller²⁰, Tadey Avcin²¹, Mikhail Kostik²², Thomas Lehman²³, Hana Malcova²⁴, edoardo marrani²⁵, Clare Pain²⁶, Anjali Patwardhan²⁷, Walter Alberto Sifuentes-Giraldo²⁸, Natalia Vasquez-Canizares²⁹, Sima Abu Alsaoud³⁰, Patricia Costa Reis³¹, Mahesh Janarthanan³², Dana Nemcova³³, Maria Jose Santos³⁴ and Nicola Helmus³⁵, ¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, ⁴Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, ⁵Cerrahpasa Medical School, Istanbul, Turkey, ⁶Division of Rheumatology, The Hospital for Sick Children; Departments of Pediatrics and Medicine, Faculty of Medicine; The Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ⁷Hospital Sant Joan de Déu. Universitat de Barcelona, Esplugues de Llobregat (Barcelona), Spain, ⁸University of Toronto, Toronto, Canada, ⁹UFRJ/UERJ, SAO PAULO, Brazil, ¹⁰UNIFESP, São Paulo, SP, Brazil, ¹¹Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil, ¹²Childrens Clinical University Hospital, Zemgales priekšpilseta, Riga, Latvia, ¹³Emma Children’s Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ¹⁴National Medical Research Center of Children's Health, Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, ¹⁵Hospital Garrahan, Buenos Aires, Argentina, ¹⁶SRCC Childrens Hospital, Mumbai, India, ¹⁷Sir Ganga Ram Hospital, Sector 37 noida, Uttar Pradesh, India, ¹⁸Ghent University Hospital, Gent, Belgium, ¹⁹Birmingham Women’s and Children’s Hospital NHSFT, Birmingham, United Kingdom, ²⁰Unicamp, Campinas, SP, Brazil, ²¹University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia, ²²Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ²³Hospital for Special Surgery, New York, NY, ²⁴Motol University Hospital, Prague, Czech Republic, ²⁵Dipartimento Neurofarba, Università di Firenze, Firenze, Italy, ²⁶Alderhey Children's NHS Foundation Trust, Liverpool, United Kingdom, ²⁷University of Missouri-Columbia, Department of Child Health, 404 N Keene Street, Columbia MO 65210, Columbia, ²⁸Hospital Universitario Ramon y Cajal, Madrid, Spain, ²⁹Children’s Hospital at Montefiore, Bronx, NY, ³⁰Caritas baby Hospital, East Jerusalem, Israel, ³¹Hospital de Santa Maria, Lisbon, Portugal, ³²SRI RAMACHANDRA INSTITUTE OF HIGHER EDUCATION AND RESEARCH, Chennai, Tamil Nadu, India, ³³MD, Prague, Czech Republic, ³⁴Hospital Garcia de Orta and Centro Académico de Medicina de Lisboa, Lisboa, Portugal, ³⁵Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile systemic scleroderma (jSSc) is an orphan disease with a prevalence in 3 in 1 000 000 children. Positive nailfold capillaroscopy (NF+) finding correlate with more…
Abstract Number: 2466 • ACR Convergence 2024
Ranked Composite Important Difference (RCID) Scores in Patients with Diffuse Cutaneous Systemic Sclerosis and Interstitial Lung Disease
Francesco Del Galdo¹, Lesley-Anne Bissell², Rozeta Simonovska³ and Margarida Alves⁴, ¹University of Leeds, Leeds, United Kingdom, ²Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach (Taunus), Germany, ⁴Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany
Background/Purpose: The ACR Composite Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) was developed to measure the probability of improvement in response to treatment in…
Abstract Number: 0703 • ACR Convergence 2024
Preliminary Results from the RECONNOITER Trial, a Phase 2 Study of AISA 021 in the Treatment of Secondary Raynaud’s, Primarily Due to Systemic Sclerosis
Andrew Sternlicht¹, Michael Shanahan², Erin Morton², Meredith Todd³, Ivana Hunt², Zoey Reed², amanda weragoda⁴, Lashika Weerakoon² and Elizabeth Briggs², ¹Tufts University Medical Center and Aisa Pharma, Inc., Boston, MA, ²Flinders Medical Centre, Adelaide, Australia, ³Aisa Pharma Pty Ltd., East Lindfield, New South Wales, Australia, ⁴F, Adelaide, Australia
Background/Purpose: While 95% of Systemic Sclerosis (SSc) patients have Raynaud’s phenomenon(RP) and many patients rate it as the most bothersome and severe symptom of their…
Abstract Number: 0957 • ACR Convergence 2024
Increased Collagen Deposition and Altered Immune Cell Profiles Are Present in Early and Late Stage Systemic Sclerosis with Gastrointestinal Involvement
Laura Much¹, Elena Pachera², Andrea Laimbacher¹, Henriette Didriksen³, Lars Aabakken⁴, Knut Ea Lundin⁴, Lumeng Li¹, Astrid Hofman¹, Pietro Bearzi⁵, Sophie Wagner⁶, Michael Scharl⁷, Øyvind Molberg⁸, Håvard Fretheim⁹, Oliver Distler¹⁰ and Anna-Maria Hoffmann-Vold⁹, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²University Hospital Zurich, Zurich, Switzerland, ³Oslo University Hospital, Moss, Norway, ⁴Department of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, ⁶University of Zurich, Schlieren, Switzerland, ⁷Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ⁹Oslo University Hospital, Oslo, Norway, ¹⁰Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Gastrointestinal tract (GIT) involvement is highly prevalent among patients with systemic sclerosis (SSc) and is associated with high morbidity and mortality. However, treatment options…
Abstract Number: 1560 • ACR Convergence 2024
Changes of Cerebral Structure and Perfusion Vary in Different Subtypes of Systemic Sclerosis: A Brain Magnetic Resonance Imaging Study
Xinyu Tong¹, Huilin He², Shihan Xu², Zihan Ning¹, Rui Shen¹, Xiaofeng Zeng³, qian wang⁴, Dong Xu⁵, Xihai zhao¹ and Zuoxiang He¹, ¹Tsinghua University, Beijing, China, ²Peking Union Medical College Hospital, Beijing, China, ³Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China, ⁴Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China, ⁵Peking Union Medical College Hospital, Dong Cheng District, Beijing, China
Background/Purpose: The characteristics of brain impairment in different subtypes of systemic sclerosis (SSc) (dcSSc, diffuse cutaneous SSc; lcSSc, limited cutaneous SSc) remain unclear. This study aimed to characterize cerebral structure and perfusion…
Abstract Number: 1586 • ACR Convergence 2024
The Relationship Between the Presence, Quantity and Distribution of Cutaneous Telangiectasia and Other Vascular Manifestations of Systemic Sclerosis
Matthew Wells¹, Robyn Domsic², Ami Shah³, Laura Hummers⁴, Aishwarya Anilkumar¹, Tracy Frech⁵, Ariane Herrick⁶, Christopher Denton⁷, Dinesh Khanna⁸ and John Pauling¹, ¹North Bristol NHS Trust, Bristol, United Kingdom, ²Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ³Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ⁴Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ⁵Vanderbilt University Medical Center, Nashville, TN, ⁶University of Manchester, UK, Aberdeen, United Kingdom, ⁷University College London, Northwood, United Kingdom, ⁸University of Michigan, Ann Arbor, MI
Background/Purpose: Telangiectasia are permanently dilated dermal postcapillary venules and are the 2nd most common manifestation (~80%) of systemic sclerosis (SSc) after Raynaud’s phenomenon (RP). The…
Abstract Number: 1823 • ACR Convergence 2024
Identification and Prediction of Systemic Sclerosis Intrinsic Subtypes Using Semi-Supervised and Supervised Learning on Gene Expression Data of Multiple Cohorts
Zhiyun Gong¹, Rezvan Parvizi², Helen Jarnagin¹, Haobin Chen³, Madeline Morrisson⁴, Tammara Wood⁵, Monique Hinchcliff⁶ and Michael Whitfield², ¹Dartmouth College, Lebanon, NH, ²Geisel School of Medicine at Dartmouth, Hanover, NH, ³Dartmouth, Lebanon, NH, ⁴Geisel School of Medicine at Dartmouth College, Hanover, NH, ⁵Dartmouth, Hanover, NH, ⁶Yale School of Medicine, Westport, CT
Background/Purpose: Systemic Sclerosis (SSc) is a molecularly heterogeneous disease. Distinct subtypes of patients have been identified based on gene expression in skin. In this study,…
Abstract Number: 2206 • ACR Convergence 2024
There Is No Difference in Major Organ Involvement Andantibody Pattern Between Diffuse and Limited Subtypejuvenile Onsetsystemic Scleroderma Patients
Ivan Foeldvari¹, Jens Klotsche², Kathryn Torok³, Ozgur Kasapcopur⁴, Amra Adrovic⁵, Brian Feldman⁶, Flavio Sztajnbok⁷, Jordi Anton⁸, Sindhu R. Johnson⁹, Maria Teresa Terreri¹⁰, Ana Sakamoto¹¹, Raju Khubchandani¹², Valda Stanevica¹³, Gülcan Özomay Baykal¹⁴, Dieneke Schonenberg-Meinema¹⁵, Eslam Al-Abadi¹⁶, Ekaterina Alexeeva¹⁷, Maria Katsicas¹⁸, Sujata Sawhney¹⁹, vanessa smith²⁰, Simone Appenzeller²¹, Tadey Avcin²², Mikhail Kostik²³, Thomas Lehman²⁴, Suzanne Li²⁵, Hana Malcova²⁶, edoardo marrani²⁷, Clare Pain²⁸, Anjali Patwardhan²⁹, Walter Alberto Sifuentes-Giraldo³⁰, Natalia Vasquez-Canizares³¹, Sima Abu Alsaoud³², Patricia Costa Reis³³, Hajek, Stefanie Hajek, Stefanie³⁴, Mahesh Janarthanan³⁵, Dana Nemcova³⁶, Siri Opsahl Hetlevik³⁷, Maria Jose Santos³⁸, Cristina Battagliotti³⁹, Lillemor Berntson⁴⁰, blanca e r bica⁴¹, Jürgen Brunner⁴², Liora Harel⁴³, Gerd Horneff⁴⁴, Daniela Kaiser⁴⁵, Dragana Lazarevic⁴⁶, Farzana Nuruzzaman⁴⁷, Mihaela Sparchez⁴⁸ and Nicola Helmus¹, ¹Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, ⁴Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, ⁵Cerrahpasa Medical School, Istanbul, Turkey, ⁶Division of Rheumatology, The Hospital for Sick Children; Departments of Pediatrics and Medicine, Faculty of Medicine; The Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ⁷UFRJ/UERJ, SAO PAULO, Brazil, ⁸Hospital Sant Joan de Déu. Universitat de Barcelona, Esplugues de Llobregat (Barcelona), Spain, ⁹University of Toronto, Toronto, Canada, ¹⁰UNIFESP, São Paulo, SP, Brazil, ¹¹Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil, ¹²SRCC Childrens Hospital, Mumbai, India, ¹³Childrens Clinical University Hospital, Zemgales priekšpilseta, Riga, Latvia, ¹⁴Umraniye Training and Research Hospital, Istanbul, Turkey, ¹⁵Emma Children’s Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ¹⁶Birmingham Women’s and Children’s Hospital NHSFT, Birmingham, United Kingdom, ¹⁷National Medical Research Center of Children's Health, Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, ¹⁸Hospital Garrahan, Buenos Aires, Argentina, ¹⁹Sir Ganga Ram Hospital, Sector 37 noida, Uttar Pradesh, India, ²⁰Ghent University Hospital, Gent, Belgium, ²¹Unicamp, Campinas, SP, Brazil, ²²University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia, ²³Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ²⁴Hospital for Special Surgery, New York, NY, ²⁵Hackensack University Medical Center, Hackensack, ²⁶Motol University Hospital, Prague, Czech Republic, ²⁷Dipartimento Neurofarba, Università di Firenze, Firenze, Italy, ²⁸Alderhey Children's NHS Foundation Trust, Liverpool, United Kingdom, ²⁹University of Missouri-Columbia, Department of Child Health, 404 N Keene Street, Columbia MO 65210, Columbia, ³⁰Hospital Universitario Ramon y Cajal, Madrid, Spain, ³¹Children’s Hospital at Montefiore, Bronx, NY, ³²Caritas baby Hospital, East Jerusalem, Israel, ³³Hospital de Santa Maria, Lisbon, Portugal, ³⁴Deutsches Zentrum für Kinder- und Jugendrheumatologie, Garmisch-Partenkirchen, Germany, ³⁵SRI RAMACHANDRA INSTITUTE OF HIGHER EDUCATION AND RESEARCH, Chennai, Tamil Nadu, India, ³⁶MD, Prague, Czech Republic, ³⁷Oslo University Hospital, Oslo, Norway, ³⁸Hospital Garcia de Orta and Centro Académico de Medicina de Lisboa, Lisboa, Portugal, ³⁹Hospital de Niños Dr Orlando Alassia, Santa Fe, Argentina, ⁴⁰Dept. of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, ⁴¹UNIVERSIDADE FEDERAL DO RIO DE JANEIRO, Rio de Janeiro, Brazil, ⁴²Medical University Innsbruck; Department of Pediatrics, Pediatric Rheumatology, Innsbruck, Austria, ⁴³Faculty of Medicine, Tel Aviv University, Tel Aviv; Pediatric Rheumatology Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel, Petach Tikva, HaMerkaz, Israel, ⁴⁴Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ⁴⁵Childrens Hospital Lucerne, Lucerne, Switzerland, ⁴⁶Dept of Pediatric Rheumatology and Immunology Clinical Center Nis, Faculty of Medicine, University of Niš, Nis, Serbia, ⁴⁷Stony Brook Children's Hospital, Stony Brook, NY, ⁴⁸Emergency Clinical Hospital for Children, Cluj-Napoca, Romania
Background/Purpose: In adult systemic sclerosis they are significant differences in clinical presentation of diffuse and limited subtype. In juvenile systemic sclerosis (jSSc) are the differences less…
Abstract Number: 2467 • ACR Convergence 2024
Elderly Systemic Sclerosis. Clinical Presentation and Outcome
Miriam Retuerto Guerrero¹, Clara Moriano², cristiana sieiro santos³, Ismael Gonzalez⁴, Ignacio Gonzalez Fernandez⁵, Carolina Díez Morrondo⁵, Carolina Alvarez Castro⁶, Paula Perez Garcia⁵, Jose Ordas Martínez⁵, Pedro Baenas Gonzalez⁵ and elvira Diez álvarez⁵, ¹Complejo Asistencial Universitario de León, Leon, Spain, ²Hospital León, LEON, Spain, ³Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ⁴Complejo Asistencial Universitario de Leon, León, Spain, ⁵Complejo Asistencial Universitario de Leon, Leon, ⁶Complejo Asistencial Universitario de Leon, Leon, Spain
Background/Purpose: Immunosenescence refers to the gradual deterioration of the immune system associated with aging, leading to an increased incidence of infections, cancer, and autoimmune diseases.…
Abstract Number: 0706 • ACR Convergence 2024
Single Center Prospective Cohort of Systemic Sclerosis Patients Who Are At-Risk for Pulmonary Hypertension
Carleigh Zahn¹, Scott Visovatti², Rosemary Gedert¹, Suiyuan Huang¹, Victor Moles¹, Amber Young¹, Vallerie McLaughlin¹ and Dinesh Khanna¹, ¹University of Michigan, Ann Arbor, MI, ²The Ohio State University, Columbus
Background/Purpose: Pulmonary hypertension (PH) is a leading cause of mortality in systemic sclerosis (SSc). We launched an IRB approved prospective study (NOVEL) in 2013 at…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].